Biotech Values

[oc631]

Anyone have any comments on likelihood this will differentiate MK-8931 from the litany of prior AD drugs targeting amyloid beta that have failed in the clinic?

So far no news has been good news concerning safety. In terms of differentiation, the angle you may be looking for could be in the study design using prodromal patients. Still a long shot. I look at MK-8931 as an underlying call option on the best long-term, risk adjusted play in biotech.

The CVR's under Cydex agreement (Captisol) expire near the end of next year so sales and licensing proceeds will go directly to LGND's bottom line. Sure a strong argument could be made the stock is currently overvalued. People have been saying that for years.